The following is a summary of the Aurora Cannabis Inc. (ACB) Q2 2025 Earnings Call Transcript:

Financial Performance:

• Aurora Cannabis Inc. reported a net revenue growth of 29% to $81.1 million, driven by a record net revenue from the global medical cannabis segment.

• Adjusted EBITDA grew 210% to $10.1 million, marking the eighth consecutive quarter of positive adjusted EBITDA.

• The company ended the quarter with $152 million in cash and cash equivalents, maintaining a strong balance sheet with no debt in the cannabis business.

Business Progress:

• Aurora focused on penetrating existing markets and entered new ones, leading to significant revenue increases particularly from global medical cannabis, which grew 41% year-over-year.

• Investments in science and innovation continue, with new product launches like CBD lozenges in collaboration with Vectura Fertin Pharma.

• Expansion efforts in international markets, notably Australia becoming a larger contributor and strategic gains in Germany and the UK.

Opportunities:

• The company is capitalizing on global medical cannabis opportunities backed by its EU GMP manufacturing facilities and regulatory expertise, particularly in the rapidly growing markets like Australia and Germany.

• Aurora is leveraging its operational excellence to maintain high margin profiles, especially in the medical cannabis segment.

Risks:

• The revenue and profitability from global medical cannabis sales can be volatile due to factors such as shipment timings and regulatory changes in international markets.

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.